Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Whitney Barton

Nurse Practitioner Corbin, KY Nurse Practitioner

NPI 1275070229 CMS profile 11178539

14949 N US Highway 25 E, Ste. 6, Corbin, KY 40701

Open in the dashboard

General payments

$14,431

714 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Whitney Barton of Corbin, KY is reported in the CMS Open Payments database as having received $14,431 across 714 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,114 174
2024 General $3,082 136
2023 General $3,353 155
2022 General $3,038 147
2021 General $1,843 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Whitney Barton
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Whitney Barton were reported at $3,114. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Whitney Barton Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,843 $135 $40–$426 $132
2022 $3,038 $152 $48–$470 $149
2023 $3,353 $166 $54–$529 $160
2024 $3,082 $173 $55–$556 $164
2025 $3,114 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $4,299 149 payments
  2. GlaxoSmithKline, LLC. $2,094 125 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,321 86 payments
  4. Grifols USA, LLC $1,309 72 payments
  5. Electromed, Inc. $1,084 45 payments
  6. Mylan Specialty L.P. $886 47 payments
  7. Genzyme Corporation $535 30 payments
  8. Amgen Inc. $426 16 payments
  9. Insmed, Inc. $322 23 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $318 19 payments
  11. Other $1,839 102 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,308 710 payments
  2. Education $124 4 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $1,827 50 payments
  2. TEZSPIRE $1,776 41 payments
  3. Prolastin-C Liquid $1,309 72 payments
  4. FASENRA $1,138 29 payments
  5. SMARTVEST $1,084 45 payments
  6. YUPELRI $1,078 59 payments
  7. TRELEGY ELLIPTA $1,032 72 payments
  8. AIRSUPRA $997 18 payments
  9. NUCALA $935 58 payments
  10. DUPIXENT $660 31 payments
  11. Other $5,118 300 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,555

Median for Nurse Practitioner: 389

Drug cost

$1,838,368

Median for Nurse Practitioner: $21,885

Branded share of claims

70.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 20 $264,594
Prolastin C Alpha-1-Proteinase Inhibitor Brand 22 $252,094
Tezspire Tezepelumab-Ekko Brand 45 $245,737
Aralast Np Alpha-1-Proteinase Inhibitor Brand 24 $218,082
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 256 $217,592
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 261 $186,719
Fasenra Pen Benralizumab Brand 18 $102,228
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 127 $74,657
Dupixent Pen Dupilumab Brand 16 $59,864
Spiriva Respimat Tiotropium Bromide Brand 90 $55,166

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$29,852

Of which drugs: $1,702

Medicare patients

220

Average age 70

Services billed

656

115 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 64%
Arthritis 49%
Ischemic heart disease 48%
Diabetes 47%
Heart failure 30%
Depression 30%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$530 45 —
YUPELRI
$405 — —
Prolastin-C Liquid
$312 22 —
DUPIXENT
$290 16 —
AIRSUPRA
$285 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

714 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record